DB
APLS

Danske Bank’s Apellis Pharmaceuticals APLS Stock Holding History

Danske Bank’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,100
Closed -$60.6K – 1433
2024
Q3 		$60.6K Buy
+2,100
New +$77.8K ﹤0.01% 1151
2024
Q2 		– Sell
-11,180
Closed -$657K – 1151
2024
Q1 		$657K Buy
+11,180
New +$713K ﹤0.01% 859

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Danske Bank's APLS Position: Q4 2024 in Review

Danske Bank sold out of Apellis Pharmaceuticals (APLS) in Q4 2024, closing a stake of 2,100 shares — an estimated $60.6K sold.

Danske Bank first reported a position in APLS in Q1 2024 and held it in 2 quarters. The position peaked at $657K in Q1 2024. 260 funds tracked by Wall St. Rank hold APLS as of Q4 2024.

  • Danske Bank reported no remaining Apellis Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Danske Bank sold 2,100 Apellis Pharmaceuticals shares in Q4 2024, an estimated $60.6K.
  • Danske Bank first reported a position in Apellis Pharmaceuticals in Q1 2024 and held it in 2 quarters.
  • Danske Bank's Apellis Pharmaceuticals position peaked at $657K in Q1 2024.
  • 260 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2024.

Based on Danske Bank's 13F filing for Q4 2024, filed 18 Mar 2026.